Publicacións en colaboración con investigadores/as de Instituto de Investigación Sanitaria Biobizkaia (12)

2023

  1. Efficacy of invasive and non-invasive methods for the treatment of Parkinson's disease: Nanodelivery and enriched environment

    International Review of Neurobiology (Academic Press Inc.), pp. 103-143

  2. Peripheral CB1 receptor blockade acts as a memory enhancer through a noradrenergic mechanism

    Neuropsychopharmacology, Vol. 48, Núm. 2, pp. 341-350

2020

  1. Changes in Day/Night Activity in the 6-OHDA-Induced Experimental Model of Parkinson’s Disease: Exploring Prodromal Biomarkers

    Frontiers in Neuroscience, Vol. 14

2019

  1. Acute L-DOPA administration reverses changes in firing pattern and low frequency oscillatory activity in the entopeduncular nucleus from long term L-DOPA treated 6-OHDA-lesioned rats

    Experimental Neurology, Vol. 322

  2. Beneficial effects of n-3 polyunsaturated fatty acids administration in a partial lesion model of Parkinson's disease: The role of glia and NRf2 regulation

    Neurobiology of Disease, Vol. 121, pp. 252-262

  3. Therapeutic potential of cannabinoids as neuroprotective agents for damaged cells conducing to movement disorders

    International Review of Neurobiology (Academic Press Inc.), pp. 229-257

2018

  1. Correction to: Deleterious Effects of VEGFR2 and RET Inhibition in a Preclinical Model of Parkinson’s Disease (Molecular Neurobiology, (2018), 55, 1, (201-212), 10.1007/s12035-017-0733-x)

    Molecular Neurobiology

  2. Deleterious effects of VEGFR2 and RET inhibition in a preclinical model of Parkinson’s disease

    Molecular Neurobiology, Vol. 55, Núm. 1, pp. 201-212

  3. Nanodelivery of cerebrolysin and rearing in enriched environment induce neuroprotective effects in a preclinical rat model of Parkinson’s disease

    Molecular Neurobiology, Vol. 55, Núm. 1, pp. 286-299

2017

  1. Morphological Changes in a Severe Model of Parkinson’s Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors

    Molecular Neurobiology, Vol. 54, Núm. 10, pp. 7722-7735

2016

  1. Intranasal administration of chitosan-coated nanostructured lipid carriers loaded with GDNF improves behavioral and histological recovery in a partial lesion model of Parkinson's disease

    Journal of Biomedical Nanotechnology, Vol. 12, Núm. 12, pp. 2220-2230

2015

  1. Topographical Distribution of Morphological Changes in a Partial Model of Parkinson’s Disease—Effects of Nanoencapsulated Neurotrophic Factors Administration

    Molecular Neurobiology, Vol. 52, Núm. 2, pp. 846-858